Nouscom
Clinical-stage biotech developing neoantigen-based cancer immunotherapies.
€120MSeries D
LeadMV
M Ventures
m-ventures.com ↗Activity from announced rounds
Activity in this selectionBiotech
M Ventures is Merck KGaA’s strategic venture investor in biotechnology, scientific tools, electronics and frontier technology. Explore its recorded Funding activity.
Investment focus
M Ventures is the strategic corporate venture investor of Merck KGaA, Darmstadt, Germany. Its mandate spans drug development, life-science tools, electronics, frontier technology and sustainability. The team combines financial and strategic objectives and works with founders and co-investors to bring scientific and technical developments toward commercial use.
Activity recorded by RoundOS
RoundOS records activity across both sides of that mandate: drug developers Remepy, TwoStep Therapeutics and TRIMTECH; research-tool businesses Lightcast and Vizgen; and optical-interconnect companies Quintessent and Polaris Electro-Optics. These published financing records describe the activity captured here, rather than the firm’s complete portfolio.
Sources
- Rounds participated in
- 6
- Confirmed lead rounds
- 1 5 roles undisclosed
- New companies
- 6 First participation on record · 0 follow-on
- Funding in participating rounds
- $220.5M 5 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
6 in this selectionTwoStep Therapeutics
A peptide-targeting platform is advancing conjugate and radioligand therapies for solid tumors.
$62.5MSeries A
Role not disclosedRemepy
Develops Hybrid Drugs combining prescription medicines with AI-driven therapeutic apps
$36MSeries A
Role not disclosedTRIMTECH Therapeutics
Develops small molecule therapies to degrade protein aggregates in neurodegenerative diseases
$47MSeed+
Role not disclosedLightcast
Develops functional single-cell analysis tools and platforms for life science research
$27MUndisclosed
Role not disclosedVizgen
Builds technologies for spatial biology and multi-omics innovation
$48MSeries A
Role not disclosed